N-Acetylcysteine as Adjuvant Therapy for COVID-19 – A Perspective on the Current State of the Evidence
Kon Ken Wong,1,2 Shaun Wen Huey Lee,3– 6 Kok Pim Kua7 1Department of Microbiology and Immunology, Hospital Canselor Tuanku Muhriz UKM, Cheras, Kuala Lumpur, Malaysia; 2Faculty of Medicine, The National University of Malaysia, Cheras, Kuala Lumpur, Malaysia; 3School of Pharmacy, Monash University, Ba...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/4eec9336dd064b7ea745524ad9264fa9 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:4eec9336dd064b7ea745524ad9264fa9 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:4eec9336dd064b7ea745524ad9264fa92021-12-02T14:35:44ZN-Acetylcysteine as Adjuvant Therapy for COVID-19 – A Perspective on the Current State of the Evidence1178-7031https://doaj.org/article/4eec9336dd064b7ea745524ad9264fa92021-07-01T00:00:00Zhttps://www.dovepress.com/n-acetylcysteine-as-adjuvant-therapy-for-covid-19--a-perspective-on-th-peer-reviewed-fulltext-article-JIRhttps://doaj.org/toc/1178-7031Kon Ken Wong,1,2 Shaun Wen Huey Lee,3– 6 Kok Pim Kua7 1Department of Microbiology and Immunology, Hospital Canselor Tuanku Muhriz UKM, Cheras, Kuala Lumpur, Malaysia; 2Faculty of Medicine, The National University of Malaysia, Cheras, Kuala Lumpur, Malaysia; 3School of Pharmacy, Monash University, Bandar Sunway, Selangor, Malaysia; 4Asian Centre for Evidence Synthesis in Population, Implementation, and Clinical Outcomes (PICO), Health and Well-being Cluster, Global Asia in the 21st Century (GA21) Platform, Monash University, Bandar Sunway, Selangor, Malaysia; 5Gerontechnology Laboratory, Global Asia in the 21st Century (GA21) Platform, Monash University, Bandar Sunway, Selangor, Malaysia; 6Faculty of Health and Medical Sciences, Taylor’s University, Bandar Sunway, Selangor, Malaysia; 7Puchong Health Clinic, Petaling District Health Office, Ministry of Health Malaysia, Petaling, Selangor, MalaysiaCorrespondence: Kok Pim Kua Email kokpimkua@gmail.comAbstract: The looming severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a long-lasting pandemic of coronavirus disease 2019 (COVID-19) around the globe with substantial morbidity and mortality. N-acetylcysteine, being a nutraceutical precursor of an important antioxidant glutathione, can perform several biological functions in mammals and microbes. It has consequently garnered a growing interest as a potential adjunctive therapy for coronavirus disease. Here, we review evidence concerning the effects of N-acetylcysteine in respiratory viral infections based on currently available in vitro, in vivo, and human clinical investigations. The repurposing of a known drug such as N-acetylcysteine may significantly hasten the deployment of a novel approach for COVID-19. Since the drug candidate has already been translated into the clinic for several decades, its established pharmacological properties and safety and side-effect profiles expedite preclinical and clinical assessment for the treatment of COVID-19. In vitro data have depicted that N-acetylcysteine increases antioxidant capacity, interferes with virus replication, and suppresses expression of pro-inflammatory cytokines in cells infected with influenza viruses or respiratory syncytial virus. Furthermore, findings from in vivo studies have displayed that, by virtue of immune modulation and anti-inflammatory mechanism, N-acetylcysteine reduces the mortality rate in influenza-infected mice animal models. The promising in vitro and in vivo results have prompted the initiation of human subject research for the treatment of COVID-19, including severe pneumonia and acute respiratory distress syndrome. Albeit some evidence of benefits has been observed in clinical outcomes of patients, precision nanoparticle design of N-acetylcysteine may allow for greater therapeutic efficacy.Keywords: N-acetylcysteine, SARS-CoV-2; COVID-19, coronavirus, repurposing approved drugs, engineering nanoparticles, virus infected cells, respiratory viral diseases, antioxidant, glutathione, T lymphocytes, immune modulating activity, anti-inflammatory response, antiviral effect, clinical translationWong KKLee SWHKua KPDove Medical Pressarticlen-acetylcysteinesars-cov-2 (2019-ncov)coronavirusrepurposing approved drugsengineering nanoparticlesvirus infected cellsrespiratory viral diseasesantioxidantglutathionet lymphocytesimmune modulating activityanti-inflammatory responseantiviral effectclinical translation.PathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 2993-3013 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
n-acetylcysteine sars-cov-2 (2019-ncov) coronavirus repurposing approved drugs engineering nanoparticles virus infected cells respiratory viral diseases antioxidant glutathione t lymphocytes immune modulating activity anti-inflammatory response antiviral effect clinical translation. Pathology RB1-214 Therapeutics. Pharmacology RM1-950 |
| spellingShingle |
n-acetylcysteine sars-cov-2 (2019-ncov) coronavirus repurposing approved drugs engineering nanoparticles virus infected cells respiratory viral diseases antioxidant glutathione t lymphocytes immune modulating activity anti-inflammatory response antiviral effect clinical translation. Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Wong KK Lee SWH Kua KP N-Acetylcysteine as Adjuvant Therapy for COVID-19 – A Perspective on the Current State of the Evidence |
| description |
Kon Ken Wong,1,2 Shaun Wen Huey Lee,3– 6 Kok Pim Kua7 1Department of Microbiology and Immunology, Hospital Canselor Tuanku Muhriz UKM, Cheras, Kuala Lumpur, Malaysia; 2Faculty of Medicine, The National University of Malaysia, Cheras, Kuala Lumpur, Malaysia; 3School of Pharmacy, Monash University, Bandar Sunway, Selangor, Malaysia; 4Asian Centre for Evidence Synthesis in Population, Implementation, and Clinical Outcomes (PICO), Health and Well-being Cluster, Global Asia in the 21st Century (GA21) Platform, Monash University, Bandar Sunway, Selangor, Malaysia; 5Gerontechnology Laboratory, Global Asia in the 21st Century (GA21) Platform, Monash University, Bandar Sunway, Selangor, Malaysia; 6Faculty of Health and Medical Sciences, Taylor’s University, Bandar Sunway, Selangor, Malaysia; 7Puchong Health Clinic, Petaling District Health Office, Ministry of Health Malaysia, Petaling, Selangor, MalaysiaCorrespondence: Kok Pim Kua Email kokpimkua@gmail.comAbstract: The looming severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a long-lasting pandemic of coronavirus disease 2019 (COVID-19) around the globe with substantial morbidity and mortality. N-acetylcysteine, being a nutraceutical precursor of an important antioxidant glutathione, can perform several biological functions in mammals and microbes. It has consequently garnered a growing interest as a potential adjunctive therapy for coronavirus disease. Here, we review evidence concerning the effects of N-acetylcysteine in respiratory viral infections based on currently available in vitro, in vivo, and human clinical investigations. The repurposing of a known drug such as N-acetylcysteine may significantly hasten the deployment of a novel approach for COVID-19. Since the drug candidate has already been translated into the clinic for several decades, its established pharmacological properties and safety and side-effect profiles expedite preclinical and clinical assessment for the treatment of COVID-19. In vitro data have depicted that N-acetylcysteine increases antioxidant capacity, interferes with virus replication, and suppresses expression of pro-inflammatory cytokines in cells infected with influenza viruses or respiratory syncytial virus. Furthermore, findings from in vivo studies have displayed that, by virtue of immune modulation and anti-inflammatory mechanism, N-acetylcysteine reduces the mortality rate in influenza-infected mice animal models. The promising in vitro and in vivo results have prompted the initiation of human subject research for the treatment of COVID-19, including severe pneumonia and acute respiratory distress syndrome. Albeit some evidence of benefits has been observed in clinical outcomes of patients, precision nanoparticle design of N-acetylcysteine may allow for greater therapeutic efficacy.Keywords: N-acetylcysteine, SARS-CoV-2; COVID-19, coronavirus, repurposing approved drugs, engineering nanoparticles, virus infected cells, respiratory viral diseases, antioxidant, glutathione, T lymphocytes, immune modulating activity, anti-inflammatory response, antiviral effect, clinical translation |
| format |
article |
| author |
Wong KK Lee SWH Kua KP |
| author_facet |
Wong KK Lee SWH Kua KP |
| author_sort |
Wong KK |
| title |
N-Acetylcysteine as Adjuvant Therapy for COVID-19 – A Perspective on the Current State of the Evidence |
| title_short |
N-Acetylcysteine as Adjuvant Therapy for COVID-19 – A Perspective on the Current State of the Evidence |
| title_full |
N-Acetylcysteine as Adjuvant Therapy for COVID-19 – A Perspective on the Current State of the Evidence |
| title_fullStr |
N-Acetylcysteine as Adjuvant Therapy for COVID-19 – A Perspective on the Current State of the Evidence |
| title_full_unstemmed |
N-Acetylcysteine as Adjuvant Therapy for COVID-19 – A Perspective on the Current State of the Evidence |
| title_sort |
n-acetylcysteine as adjuvant therapy for covid-19 – a perspective on the current state of the evidence |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/4eec9336dd064b7ea745524ad9264fa9 |
| work_keys_str_mv |
AT wongkk nacetylcysteineasadjuvanttherapyforcovid19ndashaperspectiveonthecurrentstateoftheevidence AT leeswh nacetylcysteineasadjuvanttherapyforcovid19ndashaperspectiveonthecurrentstateoftheevidence AT kuakp nacetylcysteineasadjuvanttherapyforcovid19ndashaperspectiveonthecurrentstateoftheevidence |
| _version_ |
1718391069292363776 |